LXEO (Lexeo Therapeutics) EBITDA Margin %: 0.00% (As of Mar. 2026)


LXEO Lexeo Therapeutics Inc LXEO
10 GF Score
Price $4.70
! 3 Warning Signs
View Full Analysis

What is Lexeo Therapeutics EBITDA Margin %?

Lexeo Therapeutics LXEO -3.69% 10 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates LXEO with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Lexeo Therapeutics ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lexeo Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-19.63 Mil. Lexeo Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Lexeo Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Lexeo Therapeutics  (NAS:LXEO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Lexeo Therapeutics EBITDA Margin % Related Terms

Lexeo Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Lexeo Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexeo Therapeutics EBITDA Margin % Chart

Lexeo Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial -3,054.25 -8,874.77 0.00 0.00 0.00

Lexeo Therapeutics Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LXEO vs LYEL, XFOR, ZURA: EBITDA Margin % Comparison

For the Biotechnology subindustry, Lexeo Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexeo Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lexeo Therapeutics's EBITDA Margin % falls into.


LXEO
10GF Score
Lexeo Therapeutics Inc LXEO
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexeo Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lexeo Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-97.676/0
= %

Lexeo Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-19.633/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Lexeo Therapeutics (LXEO) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lexeo Therapeutics and its competitors. According to the industry distribution chart, Lexeo Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Lexeo Therapeutics' EBITDA Margin % too high?
Lexeo Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Lexeo Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lexeo Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Lexeo Therapeutics' EBITDA Margin % compare to LYEL and XFOR?
According to the Biotechnology industry distribution chart, Lexeo Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places Lexeo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lexeo Therapeutics and its competitors. Lexeo Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexeo Therapeutics stock overvalued right now?
Lexeo Therapeutics (LXEO) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Lexeo Therapeutics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lexeo Therapeutics (LXEO), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lexeo Therapeutics Business Description

Address 345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
10GF Score

Get the complete analysis for LXEO

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.70
Price